Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "Indoco-Remedies"

31 News Found

FDA completes inspection of Indoco’s API manufacturing facility at Patalganga with zero observations
Drug Approval | September 19, 2025

FDA completes inspection of Indoco’s API manufacturing facility at Patalganga with zero observations

The inspection concluded with zero form 483 observations


Indoco receives EU GMP certificate for its sterile manufacturing facility in Goa
News | July 26, 2025

Indoco receives EU GMP certificate for its sterile manufacturing facility in Goa

This GMP certification for our sterile drug product manufacturing facility, Goa Plant II is a testament to our relentless efforts to supply quality and affordable medicines across geographies


Warren Remedies commences commercial production of oral care products
News | March 02, 2024

Warren Remedies commences commercial production of oral care products

The production started from its greenfield manufacturing facility at Aurangabad in Maharashtra


Indoco's Baddi facility receives EUGMP certification from Health Authority of Germany
Drug Approval | June 10, 2023

Indoco's Baddi facility receives EUGMP certification from Health Authority of Germany

The EU certification will support supplies of drug products registered in Europe, from this manufacturing site


Indoco receives EIR for its Plant I manufacturing facility in Goa
Drug Approval | May 04, 2023

Indoco receives EIR for its Plant I manufacturing facility in Goa

Indoco expects this change in compliance status to pave the way for approvals of ANDAs submitted from this site.


Future Packaging to redefine India Pharm industry growth: InnoPack Pharma
Packaging | June 07, 2022

Future Packaging to redefine India Pharm industry growth: InnoPack Pharma

The Innopack confex is a perfect platform for exhibitors to demonstrate their latest developments in the fields of pharmaceutical packaging, labelling, drug delivery device design and engineering.


Margins under pressure; domestic market growth to slow down: Nirmal Bang
News | January 06, 2022

Margins under pressure; domestic market growth to slow down: Nirmal Bang

A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies


IPM growth led by Covid  driven products to taper off in Q2FY22: Nirmal Bang
News | October 06, 2021

IPM growth led by Covid driven products to taper off in Q2FY22: Nirmal Bang

In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report